chloroquine has been researched along with Kidney Failure in 12 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Kidney Failure: A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloroquine and hydroxychloroquine are quinoline derivatives used to treat malaria." | 5.05 | Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. ( Cook, J; Joshi, A; Nicol, MR; Rizk, ML; Sabato, PE; Savic, RM; Wesche, D; Zheng, JH, 2020) |
| "Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases including systemic lupus, rheumatoid arthritis, sarcoidosis, and Sjogren syndrome; cutaneous disorders, antiphospholipid syndrome, and have recently been employed at higher dioses in oncology." | 2.58 | Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. ( Abdulaziz, N; McCune, WJ; Shah, AR, 2018) |
| "To evaluate the association and dose-response pattern between antimalarial drugs and overall and cause specific mortality in SLE patients." | 1.62 | Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus. ( Da, Z; Ding, X; Feng, X; Hu, H; Jin, Z; Li, J; Liu, L; Pan, W; Qian, X; Sun, L; Tan, J; Tao, J; Wang, F; Wang, M; Wei, H; Wu, J; Wu, M; Zhang, M; Zou, Y, 2021) |
| " This position statement recommends dosage adjustment for these drugs in the context of renal impairment." | 1.56 | Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function. ( Andreoli, MCC; Bastos, K; D'Avila, R; Kraychete, A; Misael, AM; Moura-Neto, JA; Nascimento, MMD; Silva, DRD, 2020) |
| "Twenty-two patients had some degree of renal failure; glomerular filtration rate (GFR) levels and albumin values were negatively associated to renal failure, while treatment with methylprednisolone decreased the probability of renal failure." | 1.35 | Prognostic factors in children with membranoproliferative glomerulonephritis type I. ( de Leon Bojorge, B; García-de la Puente, S; Orozco-Loza, IL; Zaltzman-Girshevich, S, 2008) |
| "Causes of death were first renal failure (3/8) followed by infectious complications (2/8)." | 1.30 | [Evolutive aspects of systemic lupus erythematosus in Dakar. Apropos of 30 cases]. ( Diallo, S; Diop, TM; Diouf, B; Ka, MM; Kane, A; Mbengue, M; Wade, B, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 4 (33.33) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 5 (41.67) | 2.80 |
| Authors | Studies |
|---|---|
| Pineton de Chambrun, M | 1 |
| Settegrana, C | 1 |
| Dorgham, K | 1 |
| Fenneteau, O | 1 |
| Goujon, JM | 1 |
| Mathian, A | 1 |
| Amoura, Z | 1 |
| Dos Reis Neto, ET | 1 |
| Kakehasi, AM | 1 |
| de Medeiros Pinheiro, M | 1 |
| Ferreira, GA | 1 |
| Marques, CDL | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| Sato, EI | 1 |
| Reis, APMG | 1 |
| Xavier, RM | 1 |
| Provenza, JR | 1 |
| Nicol, MR | 1 |
| Joshi, A | 1 |
| Rizk, ML | 1 |
| Sabato, PE | 1 |
| Savic, RM | 1 |
| Wesche, D | 1 |
| Zheng, JH | 1 |
| Cook, J | 1 |
| Moura-Neto, JA | 1 |
| Misael, AM | 1 |
| Silva, DRD | 1 |
| D'Avila, R | 1 |
| Andreoli, MCC | 1 |
| Kraychete, A | 1 |
| Bastos, K | 1 |
| Nascimento, MMD | 1 |
| Jin, Z | 1 |
| Wang, F | 1 |
| Pan, W | 1 |
| Liu, L | 1 |
| Wu, M | 1 |
| Hu, H | 1 |
| Ding, X | 1 |
| Wei, H | 1 |
| Zou, Y | 1 |
| Qian, X | 1 |
| Wang, M | 1 |
| Wu, J | 1 |
| Tao, J | 1 |
| Tan, J | 1 |
| Da, Z | 1 |
| Zhang, M | 1 |
| Li, J | 1 |
| Feng, X | 1 |
| Sun, L | 1 |
| Abdulaziz, N | 1 |
| Shah, AR | 1 |
| McCune, WJ | 1 |
| Doi, K | 1 |
| Yuen, PS | 1 |
| Eisner, C | 1 |
| Hu, X | 1 |
| Leelahavanichkul, A | 1 |
| Schnermann, J | 1 |
| Star, RA | 1 |
| MAKARENKO, II | 1 |
| LEVITSKII, ER | 1 |
| Albay, D | 1 |
| Adler, SG | 1 |
| Philipose, J | 1 |
| Calescibetta, CC | 1 |
| Romansky, SG | 1 |
| Cohen, AH | 1 |
| Ahmed, MH | 1 |
| Osman, MM | 1 |
| García-de la Puente, S | 1 |
| Orozco-Loza, IL | 1 |
| Zaltzman-Girshevich, S | 1 |
| de Leon Bojorge, B | 1 |
| Ka, MM | 1 |
| Diouf, B | 1 |
| Mbengue, M | 1 |
| Kane, A | 1 |
| Wade, B | 1 |
| Diallo, S | 1 |
| Diop, TM | 1 |
3 reviews available for chloroquine and Kidney Failure
| Article | Year |
|---|---|
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection.
Topics: Age Factors; Aging; Antiviral Agents; Chloroquine; Clinical Trials, Phase II as Topic; Clinical Tria | 2020 |
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administ | 2018 |
9 other studies available for chloroquine and Kidney Failure
| Article | Year |
|---|---|
Systemic chloroquine intoxication: a hint from the peripheral blood smear.
Topics: Cardiomyopathies; Chloroquine; Female; Humans; Lupus Erythematosus, Systemic; Middle Aged; Neutropen | 2020 |
Position statement from the Brazilian Society of Nephrology regarding chloroquine and hydroxychloroquine drug dose adjustment according to renal function.
Topics: Antimalarials; Brazil; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Human | 2020 |
Association of antimalarial drugs with decreased overall and cause specific mortality in systemic lupus erythematosus.
Topics: Adult; Antimalarials; China; Chloroquine; Dose-Response Relationship, Drug; Female; Humans; Hydroxyc | 2021 |
Reduced production of creatinine limits its use as marker of kidney injury in sepsis.
Topics: Animals; Antimalarials; Biomarkers; Chloroquine; Creatinine; Male; Mice; Nephrectomy; Renal Insuffic | 2009 |
[RESOCHIN IN CLINICAL INTERNAL MEDICINE AND ITS POSSIBLE SIDE EFFECTS].
Topics: Acute Kidney Injury; Antimalarials; Arthritis; Arthritis, Rheumatoid; Chloroquine; Collagen Diseases | 1964 |
Chloroquine-induced lipidosis mimicking Fabry disease.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Diagnosis, Differential; Fabry Disease; Fe | 2005 |
Why does chloroquine impair renal function?: chloroquine may modulate the renal tubular response to vasopressin either directly by inhibiting cyclic AMP generation, or indirectly via nitric oxide.
Topics: Animals; Antimalarials; Chloroquine; Cyclic AMP; Humans; Kidney Tubules; Models, Biological; Nitric | 2007 |
Prognostic factors in children with membranoproliferative glomerulonephritis type I.
Topics: Adolescent; Alkylating Agents; Child; Child, Preschool; Chloroquine; Complement System Proteins; Cyc | 2008 |
[Evolutive aspects of systemic lupus erythematosus in Dakar. Apropos of 30 cases].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Black People; Cause of Death; Chloroquine; Female; | 1998 |